JP2021523225A5 - - Google Patents

Info

Publication number
JP2021523225A5
JP2021523225A5 JP2021510283A JP2021510283A JP2021523225A5 JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5 JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5
Authority
JP
Japan
Prior art keywords
compound according
group
formula
compound
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523225A (ja
JP7379467B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030473 external-priority patent/WO2019213445A1/en
Publication of JP2021523225A publication Critical patent/JP2021523225A/ja
Publication of JP2021523225A5 publication Critical patent/JP2021523225A5/ja
Application granted granted Critical
Publication of JP7379467B2 publication Critical patent/JP7379467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510283A 2018-05-03 2019-05-02 Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 Active JP7379467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666452P 2018-05-03 2018-05-03
US62/666,452 2018-05-03
PCT/US2019/030473 WO2019213445A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (3)

Publication Number Publication Date
JP2021523225A JP2021523225A (ja) 2021-09-02
JP2021523225A5 true JP2021523225A5 (https=) 2022-04-13
JP7379467B2 JP7379467B2 (ja) 2023-11-14

Family

ID=66554488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510283A Active JP7379467B2 (ja) 2018-05-03 2019-05-02 Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法

Country Status (38)

Country Link
US (3) US10975064B2 (https=)
EP (1) EP3788045B1 (https=)
JP (1) JP7379467B2 (https=)
KR (1) KR102823195B1 (https=)
CN (1) CN112384510B (https=)
AU (1) AU2019262142B2 (https=)
BR (1) BR112020022423A2 (https=)
CA (1) CA3099018A1 (https=)
CL (1) CL2020002840A1 (https=)
CO (1) CO2020015153A2 (https=)
CR (1) CR20200582A (https=)
CY (1) CY1126152T1 (https=)
DK (1) DK3788045T3 (https=)
DO (1) DOP2020000197A (https=)
EA (1) EA202092581A1 (https=)
EC (1) ECSP20077518A (https=)
ES (1) ES2947446T3 (https=)
FI (1) FI3788045T3 (https=)
HR (1) HRP20230909T1 (https=)
HU (1) HUE062277T2 (https=)
IL (1) IL278416B2 (https=)
JO (1) JOP20200277B1 (https=)
LT (1) LT3788045T (https=)
MA (1) MA52492B1 (https=)
MD (1) MD3788045T2 (https=)
MX (1) MX2020011622A (https=)
MY (1) MY205388A (https=)
PE (1) PE20210414A1 (https=)
PH (1) PH12020551848A1 (https=)
PL (1) PL3788045T3 (https=)
PT (1) PT3788045T (https=)
RS (1) RS64418B1 (https=)
SG (1) SG11202010913PA (https=)
SI (1) SI3788045T1 (https=)
SM (1) SMT202300203T1 (https=)
UA (1) UA128160C2 (https=)
WO (1) WO2019213445A1 (https=)
ZA (1) ZA202007487B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3788045T2 (ro) * 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) * 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
SI4055021T1 (sl) * 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
JP7775288B2 (ja) * 2020-08-18 2025-11-25 ハチメド リミテッド ピリミジノン化合物およびその使用
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
WO2022237890A1 (zh) * 2021-05-14 2022-11-17 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
KR20230100646A (ko) * 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202400588A (zh) * 2022-02-28 2024-01-01 香港商維泰瑞隆（香港）生物科技有限公司 Ｒｉｐ１調製劑、其製備及用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
EP2192838A4 (en) 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN106573006A (zh) * 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
BR112017017411A2 (pt) 2015-02-13 2018-04-03 Glaxosmithkline Ip Dev Ltd Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida
EP3317269B1 (en) 2015-07-02 2022-09-21 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
ES2885474T3 (es) 2015-10-13 2021-12-13 Inst Nat Sante Rech Med Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular
AU2016340527B2 (en) 2015-10-23 2020-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
HRP20231381T1 (hr) 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
TW202019913A (zh) 2018-06-26 2020-06-01 中國科學院上海有機化學研究所 細胞壞死抑制劑及其製備方法和用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
SI4055021T1 (sl) * 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Similar Documents

Publication Publication Date Title
JP2021523225A5 (https=)
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
KR102820455B1 (ko) Shp2 활성 억제용 화합물의 제조 방법
ES2453372T3 (es) Derivados de oxadiazol como agonistas de S1P1
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
BR112020018064A2 (pt) Compostos de aminoácidos e métodos de uso
JP2018515581A5 (https=)
TW202045164A (zh) 化合物、組合物及方法
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
JP2004506611A5 (https=)
ES3062921T3 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
JP2009538910A5 (https=)
JP2024530111A (ja) アフィカムテンを調製するための工程
RS59806B1 (sr) Postupci za pripremu citotoksičnih benzodiazepinskih derivata
WO2022232838A1 (en) Expanded dosage regimens for integrin inhibitors
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
RU2011101661A (ru) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
IL276852B1 (en) A process for making soluble guinelate cyclase beads
JP2016538337A5 (https=)
BR122025028707A2 (pt) Métodos para produção de compostos para inibir atividade de shp2
CN121399105A (zh) 杂芳族dhodh抑制剂
HK40095791A (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP4782441B2 (ja) ジフェニルメチルピペラジン誘導体及びそれを含有する医薬組成物
CN120923507A (zh) 一种喹唑啉酮大环化合物及其制备方法和应用